CEACAM5 and pancreatic intraductal papillary-mucinous neoplasm: In this study, a two-marker panel of HE4 and CEA was shown to outperform CA19-9 in separating patients with IPMN from CP (SN: 74% vs. 21%), providing new insight into this field.